The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia.
Journal
European journal of drug metabolism and pharmacokinetics
ISSN: 2107-0180
Titre abrégé: Eur J Drug Metab Pharmacokinet
Pays: France
ID NLM: 7608491
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pubmed:
7
9
2018
medline:
30
6
2019
entrez:
7
9
2018
Statut:
ppublish
Résumé
Numerous studies have confirmed the influence of diabetes mellitus on the pharmacokinetics of drugs. Paracetamol (APAP) is an antipyretic that is commonly used in febrile neutropenia (FN) therapy. APAP is chiefly metabolised by glucuronidation and sulphation. This study assessed the influence of diabetes on the pharmacokinetics of paracetamol and its metabolites: glucuronide (APAP-glu) and sulfate (APAP-sulfate) in FN patients. Patients with FN received single intravenous dose 1000 mg of APAP. The FN patients were allocated to one of two groups: diabetics (DG, n = 7) or non-diabetics (NDG, n = 11). The plasma concentrations of paracetamol and its metabolites were measured with the validated high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection. Pharmacokinetic parameters (mean [SD]) of APAP in the DG and NDG groups were as follows: C No differences in the pharmacokinetics of APAP, APAP-glu and APAP-sulfate in patients with FN indicates that diabetes does not influence glucuronidation and sulfatation of paracetamol.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Numerous studies have confirmed the influence of diabetes mellitus on the pharmacokinetics of drugs. Paracetamol (APAP) is an antipyretic that is commonly used in febrile neutropenia (FN) therapy. APAP is chiefly metabolised by glucuronidation and sulphation. This study assessed the influence of diabetes on the pharmacokinetics of paracetamol and its metabolites: glucuronide (APAP-glu) and sulfate (APAP-sulfate) in FN patients.
METHODS
METHODS
Patients with FN received single intravenous dose 1000 mg of APAP. The FN patients were allocated to one of two groups: diabetics (DG, n = 7) or non-diabetics (NDG, n = 11). The plasma concentrations of paracetamol and its metabolites were measured with the validated high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection.
RESULTS
RESULTS
Pharmacokinetic parameters (mean [SD]) of APAP in the DG and NDG groups were as follows: C
CONCLUSIONS
CONCLUSIONS
No differences in the pharmacokinetics of APAP, APAP-glu and APAP-sulfate in patients with FN indicates that diabetes does not influence glucuronidation and sulfatation of paracetamol.
Identifiants
pubmed: 30187443
doi: 10.1007/s13318-018-0508-4
pii: 10.1007/s13318-018-0508-4
pmc: PMC6418056
doi:
Substances chimiques
Analgesics, Non-Narcotic
0
Glucuronides
0
Acetaminophen
362O9ITL9D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-294Références
J Chromatogr B Biomed Sci Appl. 1999 Sep 24;732(2):323-9
pubmed: 10517354
Eur J Pharm Sci. 2005 Sep;26(1):114-23
pubmed: 15985363
CNS Drug Rev. 2006 Fall-Winter;12(3-4):250-75
pubmed: 17227290
Minerva Anestesiol. 2009 Nov;75(11):644-53
pubmed: 19881460
Life Sci. 2011 Dec 5;89(23-24):834-8
pubmed: 21983297
Pain Pract. 2012 Sep;12(7):523-32
pubmed: 22524979
Pharmacol Rep. 2012;64(2):421-7
pubmed: 22661194
Clin Pharmacokinet. 2012 Aug 1;51(8):481-99
pubmed: 22668340
N Z Med J. 2013 Apr 19;126(1373):62-73
pubmed: 23797078
Antimicrob Agents Chemother. 2014 Jun;58(6):3533-7
pubmed: 24687508
Adv Hematol. 2014;2014:986938
pubmed: 25525436
Clin Drug Investig. 2015 Oct;35(10):625-32
pubmed: 26334726
J Diabetes Complications. 2017 Jan;31(1):267-272
pubmed: 27751709